Serotonin paracrine signaling in tissue fibrosis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 7, 2013, Pages 905-910

  Mann, Derek A ^a   Oakley, Fiona ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Fibrosis; Serotonin

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TRANSCRIPTION FACTOR JUND; TRANSFORMING GROWTH FACTOR BETA; SEROTONIN ANTAGONIST;

APOPTOSIS; CHEMOTAXIS; DENDRITIC CELL; EOSINOPHIL; FIBROBLAST; FIBROSIS; HEART MUSCLE FIBROSIS; HUMAN; IMMUNOCOMPETENT CELL; LIVER FIBROSIS; LIVER REGENERATION; LUNG FIBROSIS; MAST CELL; MICROVASCULATURE; MONOCYTE; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC SCLEROSIS; TISSUE REGENERATION; WOUND HEALING; VASOCONSTRICTION;

FIBROSIS; HUMANS; PARACRINE COMMUNICATION; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN ANTAGONISTS; VASOCONSTRICTION;

EID: 84877042968     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.09.009     Document Type: Review

References (74)

1. Csaba G. Presence in and effects of pineal indoleamines at very low level of phylogeny. Experientia 1993, 49:627-634.
2. Anstey M.L., Rogers S.M., Ott S.R., Burrows M., Simpson S.J. Serotonin mediates behavioral gregarization underlying swarm formation in desert locusts. Science 2009, 323:627-630.
3. Srinivasan S., Sadegh L., Elle I.C., Christensen A.G., Faergeman N.J., Ashrafi K. Serotonin regulates C. elegans fat and feeding through independent molecular mechanisms. Cell Metab. 2008, 7:533-544.
4. Ruaud A.F., Thummel C.S. Serotonin and insulin signaling team up to control growth in Drosophila. Genes Dev. 2008, 22:1851-1855.
5. Berger M., Gray J.A., Roth B.L. The expanded biology of serotonin. Annu. Rev. Med. 2009, 60:355-366.
6. Nichols D.E., Nichols C.D. Serotonin receptors. Chem. Rev. 2008, 108:1614-1641.
7. Bockaert J., Roussignol G., Becamel C., Gavarini S., Joubert L., Dumuis A., Fagni L., Marin P. GPCR-interacting proteins (GIPs): nature and functions. Biochem. Soc. Trans. 2004, 32:851-855.
8. Millan M.J., Marin P., Bockaert J. Mannoury la Cour C: signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol. Sci. 2008, 29:454-464.
9. Matsusaka S., Wakabayashi I. 5-Hydroxytryptamine as a potent migration enhancer of human aortic endothelial cells. FEBS Lett. 2005, 579:6721-6725.
10. Lang P.A., Contaldo C., Georgiev P., El-Badry A.M., Recher M., Kurrer M., Cervantes-Barragan L., Ludewig B., Calzascia T., Bolinger B., Merkler D., Odermatt B., Bader M., Graf R., Clavien P.A., Hegazy A.N., Lohning M., Harris N.L., Ohashi P.S., Hengartner H., Zinkernagel R.M., Lang K.S. Aggravation of viral hepatitis by platelet-derived serotonin. Nat. Med. 2008, 14:756-761.
11. Cloutier N., Pare A., Farndale R.W., Schumacher H.R., Nigrovic P.A., Lacroix S., Boilard E. Platelets can enhance vascular permeability. Blood 2012, 120:334-1343.
12. Kushnir-Sukhov N.M., Gilfillan A.M., Coleman J.W., Brown J.M., Bruening S., Toth M., Metcalfe D.D. 5-Hydroxytryptamine induces mast cell adhesion and migration. J. Immunol. 2006, 177:6422-6432.
13. Boehme S.A., Lio F.M., Sikora L., Pandit T.S., Lavrador K., Rao S.P., Sriramarao P. Cutting edge: serotonin is a chemotactic factor for eosinophils and functions additively with eotaxin. J. Immunol. 2004, 173:3599-3603.
14. Idzko M., Panther E., Stratz C., Muller T., Bayer H., Zissel G., Durk T., Sorichter S., Di Virgilio F., Geissler M., Fiebich B., Herouy Y., Elsner P., Norgauer J., Ferrari D. The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release. J. Immunol. 2004, 172:6011-6019.
15. Muller T., Durk T., Blumenthal B., Grimm M., Cicko S., Panther E., Sorichter S., Herouy Y., Di Virgilio F., Ferrari D., Norgauer J., Idzko M. 5-Hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One 2009, 4:e6453.
16. Durk T., Panther E., Muller T., Sorichter S., Ferrari D., Pizzirani C., Di Virgilio F., Myrtek D., Norgauer J., Idzko M. 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes. Int. Immunol. 2005, 17:599-606.
17. Soga F., Katoh N., Inoue T., Kishimoto S. Serotonin activates human monocytes and prevents apoptosis. J. Invest. Dermatol. 2007, 127:1947-1955.
18. Ghia J.E., Li N., Wang H., Collins M., Deng Y., El-Sharkawy R.T., Cote F., Mallet J., Khan W.I. Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology 2009, 137:1649-1660.
19. Young M.R., Kut J.L., Coogan M.P., Wright M.A., Young M.E., Matthews J. Stimulation of splenic T-lymphocyte function by endogenous serotonin and by low-dose exogenous serotonin. Immunology 1993, 80:395-400.
20. Slauson D.O., Walker C., Kristensen F., Wang Y., de Weck A.L. Mechanisms of serotonin-induced lymphocyte proliferation inhibition. Cell. Immunol. 1984, 84:240-252.
21. Zhu C.B., Blakely R.D., Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31:2121-2131.
22. Oates J.A., Melmon K., Sjoerdsma A., Gillespie L., Mason D.T. Release of a kinin peptide in the carcinoid syndrome. Lancet 1964, 1:514-517.
23. Fries J.F., Lindgren J.A., Bull J.M. Scleroderma-like lesions and the carcinoid syndrome. Arch. Intern. Med. 1973, 131:550-553.
24. Pavlovic M., Saiag P., Lotz J.P., Marinho E., Clerici T., Izrael V. Regression of sclerodermatous skin lesions in a patient with carcinoid syndrome treated by octreotide. Arch. Dermatol. 1995, 131:1207-1209.
25. Reimund E. Methysergide and retroperitoneal fibrosis. Lancet 1987, 1:443.
26. Fowles R.E., Cloward T.V., Yowell R.L. Endocardial fibrosis associated with fenfluramine-phentermine. N. Engl. J. Med. 1998, 338:1316.
27. Rothman R.B., Baumann M.H., Savage J.E., Rauser L., McBride A., Hufeisen S.J., Roth B.L. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000, 102:2836-2841.
28. Setola V., Hufeisen S.J., Grande-Allen K.J., Vesely I., Glennon R.A., Blough B., Rothman R.B., Roth B.L. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 2003, 63:1223-1229.
29. Antonini A., Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 2007, 6:826-829.
30. Rothman R.B., Baumann M.H. Serotonergic drugs and valvular heart disease. Expert Opin. Drug Saf. 2009, 8:317-329.
31. Yokoyama H.O., Wilson M.E., Tsuboi K.K., Stowell R.E. Regeneration of mouse liver after partial hepatectomy. Cancer Res. 1953, 13:80-85.
32. Lesurtel M., Graf R., Aleil B., Walther D.J., Tian Y., Jochum W., Gachet C., Bader M., Clavien P.A. Platelet-derived serotonin mediates liver regeneration. Science 2006, 312:104-107.
33. Nocito A., Georgiev P., Dahm F., Jochum W., Bader M., Graf R., Clavien P.A. Platelets and platelet-derived serotonin promote tissue repair after normothermic hepatic ischemia in mice. Hepatology 2007, 45:369-376.
34. Tian Y., Graf R., El-Badry A.M., Lesurtel M., Furrer K., Moritz W., Clavien P.A. Activation of serotonin receptor-2B rescues small-for-size liver graft failure in mice. Hepatology 2011, 53:253-262.
35. Furrer K., Rickenbacher A., Tian Y., Jochum W., Bittermann A.G., Kach A., Humar B., Graf R., Moritz W., Clavien P.A. Serotonin reverts age-related capillarization and failure of regeneration in the liver through a VEGF-dependent pathway. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:2945-2950.
36. Matondo R.B., Punt C., Homberg J., Toussaint M.J., Kisjes R., Korporaal S.J., Akkerman J.W., Cuppen E., de Bruin A. Deletion of the serotonin transporter in rats disturbs serotonin homeostasis without impairing liver regeneration. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296:G963-G968.
37. Omenetti A., Yang L., Gainetdinov R.R., Guy C.D., Choi S.S., Chen W., Caron M.G., Diehl A.M. Paracrine modulation of cholangiocyte serotonin synthesis orchestrates biliary remodeling in adults. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 300:G303-G315.
38. Ruddell R.G., Oakley F., Hussain Z., Yeung I., Bryan-Lluka L.J., Ramm G.A., Mann D.A. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am. J. Pathol. 2006, 169:861-876.
39. Ebrahimkhani M.R., Oakley F., Murphy L.B., Mann J., Moles A., Perugorria M.J., Ellis E., Lakey A.F., Burt A.D., Douglass A., Wright M.C., White S.A., Jaffre F., Maroteaux L., Mann D.A. Stimulating healthy tissue regeneration by targeting the 5-HT(2)B receptor in chronic liver disease. Nat. Med. 2011, 17:1668-1673.
40. Fausto N., Campbell J.S., Riehle K.J. Liver regeneration. Hepatology 2006, 43:S45-S53.
41. Gressner A.M., Weiskirchen R., Breitkopf K., Dooley S. Roles of TGF-beta in hepatic fibrosis. Front. Biosci. 2002, 7:d793-d807.
42. Graham J.R. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Trans. Am. Clin. Climatol. Assoc. 1967, 78:79-92.
43. Wilson M.S., Wynn T.A. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2009, 2:103-121.
44. Almeida I., Faria R., Vita P., Vasconcelos C. Systemic sclerosis refractory disease: from the skin to the heart. Autoimmun. Rev. 2011, 10:693-701.
45. van der Veen M.J., Dekker J.J., Dinant H.J., van Soesbergen R.M., Bijlsma J.W. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J. Rheumatol. 1995, 22:1766-1768.
46. Denham J.W., Hauer-Jensen M. The radiotherapeutic injury-a complex 'wound'. Radiother. Oncol. 2002, 63:129-145.
47. Lee S.L., Wang W.W., Lanzillo J.J., Fanburg B.L. Regulation of serotonin-induced DNA synthesis of bovine pulmonary artery smooth muscle cells. Am. J. Physiol. 1994, 266:L53-L60.
48. Welsh D.J., Harnett M., MacLean M., Peacock A.J. Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter. Am. J. Respir. Crit. Care Med. 2004, 170:252-259.
49. Johnson D.E., Georgieff M.K. Pulmonary neuroendocrine cells. Their secretory products and their potential roles in health and chronic lung disease in infancy. Am. Rev. Respir. Dis. 1989, 140:1807-1812.
50. Eddahibi S., Guignabert C., Barlier-Mur A.M., Dewachter L., Fadel E., Dartevelle P., Humbert M., Simonneau G., Hanoun N., Saurini F., Hamon M., Adnot S. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 2006, 113:1857-1864.
51. Maclean M.R., Dempsie Y. The serotonin hypothesis of pulmonary hypertension revisited. Adv. Exp. Med. Biol. 2010, 661:309-322.
52. MacLean M.R., Herve P., Eddahibi S., Adnot S. 5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br. J. Pharmacol. 2000, 131:161-168.
53. Demoulin J.C., Bertholet M., Soumagne D., David J.L., Kulbertus H.E. 5-HT2-receptor blockade in the treatment of heart failure. A preliminary study. Lancet 1981, 1:1186-1188.
54. Dumitrascu R., Kulcke C., Konigshoff M., Kouri F., Yang X., Morrell N., Ghofrani H.A., Weissmann N., Reiter R., Seeger W., Grimminger F., Eickelberg O., Schermuly R.T., Pullamsetti S.S. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur. Respir. J. 2011, 37:1104-1118.
55. Launay J.M., Herve P., Peoc'h K., Tournois C., Callebert J., Nebigil C.G., Etienne N., Drouet L., Humbert M., Simonneau G., Maroteaux L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. 2002, 8:1129-1135.
56. Morecroft I., Heeley R.P., Prentice H.M., Kirk A., MacLean M.R. 5-Hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br. J. Pharmacol. 1999, 128:730-734.
57. Konigshoff M., Dumitrascu R., Udalov S., Amarie O.V., Reiter R., Grimminger F., Seeger W., Schermuly R.T., Eickelberg O. Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention. Thorax 2010, 65:949-955.
58. Fabre A., Marchal-Somme J., Marchand-Adam S., Quesnel C., Borie R., Dehoux M., Ruffie C., Callebert J., Launay J.M., Henin D., Soler P., Crestani B. Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. Eur. Respir. J. 2008, 32:426-436.
59. Hutcheson J.D., Setola V., Roth B.L., Merryman W.D. Serotonin receptors and heart valve disease-it was meant 2B. Pharmacol. Ther. 2011, 132:146-157.
60. Nebigil C.G., Choi D.S., Dierich A., Hickel P., Le Meur M., Messaddeq N., Launay J.M., Maroteaux L. Serotonin 2B receptor is required for heart development. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:9508-9513.
61. Nebigil C.G., Jaffre F., Messaddeq N., Hickel P., Monassier L., Launay J.M., Maroteaux L. Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy. Circulation 2003, 107:3223-3229.
62. Jaffre F., Callebert J., Sarre A., Etienne N., Nebigil C.G., Launay J.M., Maroteaux L., Monassier L. Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts. Circulation 2004, 110:969-974.
63. Jaffre F., Bonnin P., Callebert J., Debbabi H., Setola V., Doly S., Monassier L., Mettauer B., Blaxall B.C., Launay J.M., Maroteaux L. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ. Res. 2009, 104:113-123.
64. Pietri M., Schneider B., Mouillet-Richard S., Ermonval M., Mutel V., Launay J.M., Kellermann O. Reactive oxygen species-dependent TNF-alpha converting enzyme activation through stimulation of 5-HT2B and alpha1D autoreceptors in neuronal cells. FASEB J. 2005, 19:1078-1087.
65. Monassier L., Laplante M.A., Jaffre F., Bousquet P., Maroteaux L., de Champlain J. Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice. Hypertension 2008, 52:301-307.
66. Generini S., Matucci Cerinic M. Raynaud's phenomenon and vascular disease in systemic sclerosis. Adv. Exp. Med. Biol. 1999, 455:93-100.
67. Macdonald R.A., Robbins S.L., Mallory G.K. Dermal fibrosis following subcutaneous injections of serotonin creatinine sulphate. Proc. Soc. Exp. Biol. Med. 1958, 97:334-337.
68. Roddie I.C., Shepherd J.T., Whelan R.F. The action of 5-hydroxytryptamine on the blood vessels of the human hand and forearm. Br. J. Pharmacol. Chemother. 1955, 10:445-450.
69. Sternberg E.M., Van Woert M.H., Young S.N., Magnussen I., Baker H., Gauthier S., Osterland C.K. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N. Engl. J. Med. 1980, 303:782-787.
70. Biondi M.L., Marasini B., Bianchi E., Agostoni A. Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon. Int. J. Cardiol. 1988, 19:335-339.
71. Klimiuk P.S., Grennan A., Weinkove C., Jayson M.I. Platelet serotonin in systemic sclerosis. Ann. Rheum. Dis. 1989, 48:586-589.
72. Dees C., Akhmetshina A., Zerr P., Reich N., Palumbo K., Horn A., Jungel A., Beyer C., Kronke G., Zwerina J., Reiter R., Alenina N., Maroteaux L., Gay S., Schett G., Distler O., Distler J.H. Platelet-derived serotonin links vascular disease and tissue fibrosis. J. Exp. Med. 2011, 208:961-972.
73. Palumbo K., Zerr P., Tomcik M., Vollath S., Dees C., Akhmetshina A., Avouac J., Yaniv M., Distler O., Schett G., Distler J.H. The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Ann. Rheum. Dis. 2011, 70:1320-1326.
74. McLaughlin V.V. Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur. Respir. Rev. 2011, 20:262-269.